MIRA Pharmaceuticals, Inc. Common Stock

Day range

$0.52 – $0.65

Open

$0.65

Prev close

$0.62

Volume

205.08K

Market cap

$26.03M

Shares out

42.02M

P/E

—

P/S

—

P/B

3.19

P/FCF

—

ROE

-380.2%

ROA

-378.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 22, 2026

  The study demonstrated that once-daily oral MIRA-55 significantly reduced mechanical and thermal pain hypersensitivity compared with vehicle-treated animals (p < 0.001). MIRA-55 achieved pain-relieving effects comparable in magnitude to celecoxib (Celebrex®), with effects sustained throughout the study without evidence of tolerance or adverse clinical signs.

• Annual meeting resultsSep 16, 2026

  At the Annual Meeting, three proposals were submitted to the Company's stockholders. The proposals are described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on July 28, 2026. Each proposal was approved by the Company's stockholders.

• Listing deficiency noticeJul 31, 2026

  On July 27, 2026, Mira Pharmaceuticals, Inc. (the "Company") received a letter (the "Letter") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock ("Common Stock") for the 30 consecutive business days ended July 24, 2026, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

• Clinical trial resultsJun 25, 2026

  Using standard preclinical models that researchers use to characterize THC-like compounds, the data showed that Mira-55 did not produce the locomotor suppression or catalepsy associated with THC. Mira-55 produced a modest reduction in body temperature, but unlike the corresponding THC effect, this was not reversed by rimonabant, a CB1 receptor antagonist, suggesting a mechanism distinct from classical CB1 agonism. In a separate assay, Mira-55 demonstrated anxiolytic activity, in contrast to anxiogenic activity observed with rimonabant.

• Regulatory decisionJun 17, 2026

  the Company received an acknowledgment of receipt from the FDA confirming acceptance of the Phase 2a clinical trial protocol submission for Protocol Mira-002

Days to cover

2.4

Short interest

408.84K

Avg volume

168.67K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Why Mira Pharmaceuticals Shares Rose 69% After Hours?
  positiveBenzinga· Oct 16, 2025
• Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
  positiveGlobeNewswire Inc.· Aug 12, 2025
• EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million
  positiveBenzinga· May 8, 2025
• Kernel and Mira Launch Industry’s First $300M Secured AI API
  positiveGlobeNewswire Inc.· Feb 6, 2025
• Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
  Benzinga· Mar 27, 2024